Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Xu, Jian-Ming"" wg kryterium: Autor


Wyświetlanie 1-15 z 15
Tytuł :
Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours.
Autorzy :
Raymond E; Department of Medical Oncology, Paris Saint-Joseph Hospital Group, Paris, France.
Kulke MH; Program in Neuroendocrine and Carcinoid Tumors, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Qin S; PLA Cancer Center, Nanjing Bayi Hospital, Nanjing, China.
Yu X; Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Schenker M; Centrul de Oncologie Sf. Nectarie, Oncologie Medicala, Craiova, Romania.
Cubillo A; Hospital Universitario Madrid Sanchinarro, Centro Integral Oncológico Clara Campal, Madrid, Spain.
Lou W; Zhongshan Hospital, Fudan University, Shanghai, China.
Tomasek J; Faculty of Medicine, Masaryk Memorial Cancer Institute, Masaryk University, Brno, Czech Republic.
Thiis-Evensen E; Department of Gastroenterology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Xu JM; No. 307 Hospital, Academy of Military Medical Sciences, Beijing, China.
Croitoru AE; Department of Medical Oncology, Fundeni Clinical Institute, Bucharest, Romania.
Khasraw M; Andrew Love Cancer Center, Geelong Hospital, Victoria, Victoria, Australia.
Sedlackova E; Všeobecné Fakultní Nemocnice v Praze Onkologická Klinika, Prague, Czech Republic.
Borbath I; Hepato-Gastroenterology Department, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Ruff P; Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Oberstein PE; Division of Hematology/Oncology, Columbia University Medical Center, New York, New York, USA.
Ito T; Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Jia L; China-Japan Friendship Hospital, Beijing, China.
Hammel P; Service d'Oncologie Digestive, Hôpital Beaujon, Clichy, France.
Shen L; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of GI Oncology, Peking University Cancer Hospital and Institute, Beijing, China.
Shrikhande SV; GI and HPB Surgical Oncology, Tata Memorial Hospital, Mumbai, India.
Shen Y; West China Hospital of Sichuan University, Chengdu, China.
Sufliarsky J; 2nd Department of Oncology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
Khan GN; Henry Ford Health System, Detroit, Michigan, USA.
Morizane C; National Cancer Center, Tokyo, Japan.
Galdy S; Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, Milan, Italy.
Khosravan R; Pfizer Oncology, Pfizer Inc., San Diego, California, USA.
Fernandez KC; Pfizer Oncology, Pfizer Inc., Cambridge, Massachusetts, USA.
Rosbrook B; Pfizer Oncology, Pfizer Inc., San Diego, California, USA.
Fazio N; Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, Milan, .
Pokaż więcej
Źródło :
Neuroendocrinology [Neuroendocrinology] 2018; Vol. 107 (3), pp. 237-245. Date of Electronic Publication: 2018 Jul 10.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Neuroendocrine Tumors/*drug therapy
Pancreatic Neoplasms/*drug therapy
Sunitinib/*therapeutic use
Adult ; Aged ; Antineoplastic Agents/adverse effects ; Disease-Free Survival ; Female ; Humans ; Male ; Middle Aged ; Neuroendocrine Tumors/mortality ; Neuroendocrine Tumors/pathology ; Pancreatic Neoplasms/mortality ; Pancreatic Neoplasms/pathology ; Sunitinib/adverse effects ; Survival Rate
Czasopismo naukowe
Tytuł :
Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study.
Autorzy :
Xu JM; Department of Gastrointestinal Oncology, The Affiliated Hospital Cancer Center (The 307th Hospital of Chinese People's Liberation Army), Academy of Military Medical Sciences, Beijing, China.
Wang Y; Department of Gastrointestinal Oncology, The Affiliated Hospital Cancer Center (The 307th Hospital of Chinese People's Liberation Army), Academy of Military Medical Sciences, Beijing, China.
Chen YL; Department of Gastrointestinal Oncology, The Affiliated Hospital Cancer Center (The 307th Hospital of Chinese People's Liberation Army), Academy of Military Medical Sciences, Beijing, China.
Jia R; Department of Gastrointestinal Oncology, The Affiliated Hospital Cancer Center (The 307th Hospital of Chinese People's Liberation Army), Academy of Military Medical Sciences, Beijing, China.
Li J; Department of Gastrointestinal Oncology, Peking University Cancer Hospital, Beijing, China.
Gong JF; Department of Gastrointestinal Oncology, Peking University Cancer Hospital, Beijing, China.
Li J; Clinical and Regulatory Department, Hutchison MediPharma Limited, Shanghai, China.
Qi C; Clinical and Regulatory Department, Hutchison MediPharma Limited, Shanghai, China.
Hua Y; Clinical and Regulatory Department, Hutchison MediPharma Limited, Shanghai, China.
Tan CR; Clinical and Regulatory Department, Hutchison MediPharma Limited, Shanghai, China.
Wang J; Drug Metabolism and Pharmacokinetic Department, Hutchison MediPharma Limited, Shanghai, China.
Li K; Drug Metabolism and Pharmacokinetic Department, Hutchison MediPharma Limited, Shanghai, China.
Sai Y; Drug Metabolism and Pharmacokinetic Department, Hutchison MediPharma Limited, Shanghai, China.
Zhou F; Oncology Department, Hutchison MediPharma Limited, Shanghai, China.
Ren YX; Oncology Department, Hutchison MediPharma Limited, Shanghai, China.
Qing WG; Oncology Department, Hutchison MediPharma Limited, Shanghai, China.
Jia H; Chemistry Department, Hutchison MediPharma Limited, Shanghai, China.
Su WG; Chemistry Department, Hutchison MediPharma Limited, Shanghai, China.
Shen L; Department of Gastrointestinal Oncology, Peking University Cancer Hospital, Beijing, China.
Pokaż więcej
Źródło :
Oncotarget [Oncotarget] 2017 Jun 27; Vol. 8 (26), pp. 42076-42086.
Typ publikacji :
Clinical Trial, Phase I; Journal Article
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Neoplasms/*drug therapy
Neoplasms/*pathology
Protein Kinase Inhibitors/*therapeutic use
Adult ; Aged ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/pharmacokinetics ; Drug Monitoring ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Neoplasm Staging ; Neoplasms/diagnosis ; Neoplasms/mortality ; Prognosis ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/pharmacokinetics ; Research Design ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Transdermal granisetron for the prevention of nausea and vomiting following moderately or highly emetogenic chemotherapy in Chinese patients: a randomized, double-blind, phase III study.
Autorzy :
Yang LQ; Department of Clinical Medicine, Nanjing Medical University, Nanjing 211166, China; Department of Medical Oncology, Nanjing Bayi Hospital, Nanjing 210002, China.
Sun XC; Department of Clinical Medicine, Nanjing Medical University, Nanjing 211166, China; Department of Radiotherapy, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China. .
Qin SK; Department of Medical Oncology, Nanjing Bayi Hospital, Nanjing 210002, China.
Chen YX; Department of Medical Oncology, Nanjing Bayi Hospital, Nanjing 210002, China.
Zhang HL; Department of Medical Oncology, Tangdu Hospital, Xi'an 710038, China.
Cheng Y; Department of Medical Oncology, Jilin Cancer Hospital, Changchun 130012, China.
Chen ZD; Department of Medical Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China.
Shi JH; Department of Medical Oncology, Linyi Cancer Hospital, Linyi 276002, China.
Wu Q; Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu 233099, China.
Bai YX; Department of Medical Oncology, Heilongjiang Province Cancer Hospital, Ha'er'bin 150081, China.
Han BH; Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai 200030, China.
Liu W; Department of Medical Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
Ouyang XN; Department of Medical Oncology, Fuzhou General Hospital of Nanjing Military Command, Fuzhou 350025, China.
Liu JW; Department of Medical Oncology, The First Hospital of Dalian Medical University, Dalian 116011, China.
Zhang ZH; Department of Medical Oncology, Sichuan Province Cancer Hospital, Chengdu 610042, China.
Li YQ; Department of Medical Oncology, The Cancer Hospital of Guangxi Medical University, Nanning 530021, China.
Xu JM; Department of Medical Oncology, The 307th Hospital of PLA, Beijing 100071, China.
Yu SY; Department of Medical Oncology, Wuhan Tongji Hospital, Wuhan 430012, China.
Pokaż więcej
Źródło :
Chinese clinical oncology [Chin Clin Oncol] 2016 Dec; Vol. 5 (6), pp. 79.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Antiemetics/*administration & dosage
Antineoplastic Agents/*adverse effects
Granisetron/*administration & dosage
Nausea/*prevention & control
Vomiting/*prevention & control
Administration, Cutaneous ; Adolescent ; Adult ; Aged ; Antineoplastic Agents/therapeutic use ; Double-Blind Method ; Female ; Humans ; Male ; Middle Aged ; Nausea/drug therapy ; Vomiting/drug therapy ; Young Adult
Czasopismo naukowe
Tytuł :
[Safety and efficacy of gefitinib for treatment of advanced non-small cell lung cancer].
Autorzy :
Xu JM; Cancer Center, 307 Hospital, Academy of Military Medical Sciences, Beijing 100071, China. />Li YM
Liu XQ
Zhang Y
Han Y
Yang WW
Song ST
Pokaż więcej
Źródło :
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2007 Jan; Vol. 29 (1), pp. 66-9.
Typ publikacji :
Clinical Trial; Journal Article
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Lung Neoplasms/*drug therapy
Quinazolines/*therapeutic use
Adenocarcinoma/drug therapy ; Adenocarcinoma/pathology ; Aged ; Antineoplastic Agents/adverse effects ; Carcinoma, Non-Small-Cell Lung/pathology ; Carcinoma, Squamous Cell/drug therapy ; Carcinoma, Squamous Cell/pathology ; Diarrhea/chemically induced ; Disease Progression ; Exanthema/chemically induced ; Female ; Gefitinib ; Humans ; Kaplan-Meier Estimate ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Neoplasm Staging ; Quinazolines/adverse effects ; Remission Induction ; Sex Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Phase II trial of sequential gefitinib after minor response or partial response to chemotherapy in Chinese patients with advanced non-small-cell lung cancer.
Autorzy :
Xu JM; Beijing 307 Hospital Cancer Center, Beijing, China. />Han Y
Li YM
Zhao CH
Wang Y
Paradiso A
Pokaż więcej
Źródło :
BMC cancer [BMC Cancer] 2006 Dec 16; Vol. 6, pp. 288. Date of Electronic Publication: 2006 Dec 16.
Typ publikacji :
Clinical Trial, Phase II; Journal Article
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Lung Neoplasms/*drug therapy
Quinazolines/*therapeutic use
Adenocarcinoma/drug therapy ; Adenocarcinoma/pathology ; Adult ; Antineoplastic Agents/toxicity ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/pathology ; China ; Disease Progression ; Female ; Gefitinib ; Humans ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Male ; Neoplasm Staging ; Patient Selection ; Quinazolines/toxicity ; Survival Analysis
Czasopismo naukowe
Tytuł :
[Current status of the study of the mechanism of epidermal growth factor receptor targeting drug therapy and their related markers].
Autorzy :
Wang Y
Xu JM
Song ST
Pokaż więcej
Źródło :
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2005 Sep; Vol. 27 (9), pp. 573-6.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Delivery Systems*
Antineoplastic Agents/*administration & dosage
ErbB Receptors/*antagonists & inhibitors
Lung Neoplasms/*drug therapy
Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal, Humanized ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Cetuximab ; Gefitinib ; Humans ; Protein Kinase Inhibitors/administration & dosage ; Quinazolines/administration & dosage
Czasopismo naukowe
Tytuł :
The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839).
Autorzy :
Azzariti A; Clinical Experimental Oncology Laboratory, National Cancer Institute, Bari, Italy.
Xu JM
Porcelli L
Paradiso A
Pokaż więcej
Źródło :
Biochemical pharmacology [Biochem Pharmacol] 2004 Jul 01; Vol. 68 (1), pp. 135-44.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Apoptosis*
Antineoplastic Agents/*pharmacology
Camptothecin/*pharmacology
Quinazolines/*pharmacology
Antineoplastic Agents/administration & dosage ; Camptothecin/administration & dosage ; Camptothecin/analogs & derivatives ; Cell Cycle/drug effects ; Cell Division/drug effects ; Colonic Neoplasms/pathology ; DNA Topoisomerases, Type I/metabolism ; Drug Synergism ; ErbB Receptors/metabolism ; Gefitinib ; HT29 Cells ; Humans ; Irinotecan ; Quinazolines/administration & dosage ; Signal Transduction/drug effects ; Signal Transduction/physiology ; Tumor Cells, Cultured
Czasopismo naukowe
Tytuł :
[The effect of IRESSA on H22 mouse hepatocellular carcinoma].
Autorzy :
Zhu BD; School of Oncology, Peking University and Beijing Institute for Cancer Research, Beijing Cancer Hospital, Beijing 10036, China.
Yuan SJ
Xu JM
Zhao QC
Li X
Li Y
Hao LH
Pokaż więcej
Źródło :
Zhonghua yi xue za zhi [Zhonghua Yi Xue Za Zhi] 2004 Apr 17; Vol. 84 (8), pp. 684-6.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Carcinoma, Hepatocellular/*drug therapy
Liver Neoplasms/*drug therapy
Quinazolines/*therapeutic use
Animals ; Cisplatin/therapeutic use ; Disease Models, Animal ; Gefitinib ; Mice ; Random Allocation ; Treatment Outcome
Czasopismo naukowe
Tytuł :
[Comparison of endocrine therapy and chemotherapy for bone metastasis of breast cancer].
Autorzy :
Yan M; Department of Breast Cancer, No.307 Hospital, Academy of Military Medical Sciences, Beijing 100039, China.
Song ST
Jiang ZF
Zhang SH
Liu XQ
Xu JM
Wang T
Luo WD
Pokaż więcej
Źródło :
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2004 Mar; Vol. 26 (3), pp. 177-80.
Typ publikacji :
Comparative Study; English Abstract; Journal Article
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Bone Neoplasms/*secondary
Breast Neoplasms/*therapy
Bone Neoplasms/therapy ; Breast Neoplasms/mortality ; Female ; Humans ; Prognosis ; Retrospective Studies ; Survival Rate ; Treatment Failure
Czasopismo naukowe
Tytuł :
Characterization of sequence-dependent synergy between ZD1839 ("Iressa") and oxaliplatin.
Autorzy :
Xu JM; Beijing 307 Hospital Cancer Center, Beijing 100039, China.
Azzariti A
Severino M
Lu B
Colucci G
Paradiso A
Pokaż więcej
Źródło :
Biochemical pharmacology [Biochem Pharmacol] 2003 Aug 15; Vol. 66 (4), pp. 551-63.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents/*pharmacology
Organoplatinum Compounds/*pharmacology
Quinazolines/*pharmacology
Apoptosis/drug effects ; Cell Cycle/drug effects ; DNA Adducts/metabolism ; Drug Synergism ; ErbB Receptors/metabolism ; Gefitinib ; HT29 Cells ; Humans ; Organoplatinum Compounds/administration & dosage ; Oxaliplatin ; Phosphorylation ; Platinum/metabolism ; Quinazolines/administration & dosage ; Quinazolines/pharmacokinetics ; gamma-Glutamyltransferase/metabolism
Czasopismo naukowe
Tytuł :
The Sequence-Dependent Cytotoxic Effect of Trastuzumab in Combination With 5-Fluorouracil or Cisplatin on Gastric Cancer Cell Lines.
Autorzy :
Li, Xiao-Ling
Yi, Shao-Qiong
Xu, Jian-Ming
Zhang, Yang
Yingying-Feng
Chen, Wei
Song, San-Tai
Pokaż więcej
Temat :
STOMACH cancer -- Treatment
ANTINEOPLASTIC agents
TRASTUZUMAB
FLUOROURACIL
CISPLATIN
CLINICAL trials
CHEMOTHERAPY (Cancer)
COMPLEMENTATION (Genetics)
Źródło :
Cancer Investigation; Nov2010, Vol. 28 Issue 10, p1038-1047, 10p, 2 Charts, 6 Graphs
Czasopismo naukowe
    Wyświetlanie 1-15 z 15

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies